{"id":169816,"date":"2024-07-15T02:35:42","date_gmt":"2024-07-15T06:35:42","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/acumen-pharmaceuticals-to-present-patient-experience-and-biomarker-insights-from-phase-1-intercept-ad-study-at-the-alzheimers-association\/"},"modified":"2024-08-17T16:50:38","modified_gmt":"2024-08-17T20:50:38","slug":"acumen-pharmaceuticals-to-present-patient-experience-and-biomarker-insights-from-phase-1-intercept-ad-study-at-the-alzheimers-association","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medical-school\/acumen-pharmaceuticals-to-present-patient-experience-and-biomarker-insights-from-phase-1-intercept-ad-study-at-the-alzheimers-association.php","title":{"rendered":"Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer\u2019s Association&#8230;"},"content":{"rendered":"<p><![CDATA[NEWTON, Mass., July  11, 2024  (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (A?Os) for the treatment of Alzheimer\u2019s disease (AD),\u00a0today announced that the Company will present patient experience and biomarker data from its Phase 1 INTERCEPT-AD study of sabirnetug (ACU193) at the Alzheimer\u2019s Association International Conference (AAIC\u00ae) 2024 taking place in Philadelphia and online from July 28 \u2013 Aug. 1, 2024. The posters expand upon biomarker data associated with sabirnetug, methods for detecting levels of sabirnetug in cerebrospinal fluid (CSF), and provide insights on patients\u2019 experiences in the INTERCEPT-AD study to inform future clinical trial considerations for sabirnetug.]]><\/p>\n<p>Read more:<br \/>\n<a target=\"_blank\" href=\"https:\/\/www.globenewswire.com\/news-release\/2024\/07\/11\/2911782\/0\/en\/Acumen-Pharmaceuticals-to-Present-Patient-Experience-and-Biomarker-Insights-from-Phase-1-INTERCEPT-AD-Study-at-the-Alzheimer-s-Association-International-Conference-AAIC-2024.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer\u2019s Association...\" rel=\"noopener\">Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer\u2019s Association...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Read more: Acumen Pharmaceuticals to Present Patient Experience and Biomarker Insights from Phase 1 INTERCEPT-AD Study at the Alzheimer\u2019s Association... <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/medical-school\/acumen-pharmaceuticals-to-present-patient-experience-and-biomarker-insights-from-phase-1-intercept-ad-study-at-the-alzheimers-association.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[36],"tags":[],"class_list":["post-169816","post","type-post","status-publish","format-standard","hentry","category-medical-school"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/169816"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=169816"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/169816\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=169816"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=169816"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=169816"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}